Your browser does not support JavaScript!

South Korea’s Healthcare Industry in 2025: Performance, Innovation, and Global Outlook

General Report May 7, 2025
goover

TABLE OF CONTENTS

  1. Summary
  2. Current Bio-Health Landscape
  3. Bio-Health Industry Growth Outlook
  4. AI and Bio Convergence in Healthcare
  5. Digital Transformation and E-Commerce
  6. Clinical Trials Leadership
  7. International Collaborations and Medical Device Sector
  8. Medical Education and Social Demand
  9. Medical Dispute Resolution for Foreign Patients
  10. Conclusion

1. Summary

  • As of May 7, 2025, the healthcare industry in South Korea stands at a critical junction, showcasing both resilience and promise amidst a fluctuating global landscape. In 2023, bio-health sales experienced a slight contraction, decreasing by 0.7% to ₩133 trillion (approximately $93.3 billion). Despite this downturn, sectors such as pharmaceuticals and research and development (R&D) exhibited notable growth, highlighting the underlying strength of the industry. Specifically, the pharmaceutical sector recorded sales of ₩53.8 trillion, marking a 6.1% increase from the previous year, underscoring the enduring commitment to innovation. The robust performance of the cosmetics segment, which grew by 7.9%, alongside the challenges faced by the medical devices sector—where sales fell by 15.7%—paints a complex picture of the current market dynamics.

  • Looking ahead, strategic momentum is building for South Korea's bio-health industry, which is projected to rank 8th globally by 2030, fueled by an anticipated nearly 9% annual growth rate. Key drivers set to propel this growth include the rapid integration of AI diagnostics, the convergence of biotechnology with healthcare, and the expansion of the e-commerce sector dedicated to health products. Furthermore, a fortified clinical trial framework supports innovation and access to healthcare solutions, effectively positioning South Korea as a competitive player in the global arena. Notably, international partnerships, such as those fostered through the EU’s Healthcare & Medical Equipment Korea 2025 mission, along with enhanced dispute-resolution mechanisms for foreign patients, accentuate the country's ambitions for leadership in global healthcare.

  • The evolving landscape of medical education, coupled with outcries for more qualified healthcare professionals, further emphasizes the need for a responsive training system aligned with national healthcare demands. Overall, while challenges remain, the prospects for South Korea's healthcare sector are promising, driven by innovation, strategic partnerships, and a commitment to global engagement.

2. Current Bio-Health Landscape

  • 2-1. 2023 Industry Sales Trends

  • In 2023, the bio-health industry in South Korea experienced a slight decline in overall sales, dipping by 0.7% to reach ₩133 trillion (approximately $93.3 billion). This figure, while indicative of a contraction, masks the robust performance of specific sectors within the industry. The pharmaceutical sector stood out, recording sales of ₩53.8 trillion, which is a 6.1% increase compared to 2022. This growth reflects a persistent trend towards innovation and expansion in pharmaceutical research and development (R&D), even as other segments, such as medical devices, faced declines. The cosmetics segment also demonstrated resilience, with revenues rising by 7.9% to ₩42 trillion despite the overall downturn in the bio-health landscape. However, the medical devices sector reported a significant drop of 15.7%, generating ₩37.9 trillion, highlighting the challenges faced in this segment amidst a rapidly evolving market.

  • 2-2. Pharmaceutical and R&D Performance

  • The pharmaceutical sector has emerged as the cornerstone of South Korea's bio-health industry, particularly in light of its continued expansion. In 2023, R&D investment surged by 18.5%, reaching ₩7.4 trillion, signaling the sector's commitment to innovation and its role in positioning South Korea within the global pharmaceutical landscape. The increase in R&D spending coincides with a workforce growth in the industry, where overall employment rose by 3.1% to 352, 784 employees. Importantly, the majority of this workforce is concentrated in the pharmaceutical sector, where employment reached 102, 141 individuals. This investment and growth in human capital not only enhance the potential for scientific breakthroughs but also support the development of competitive products that can sustain the nation's economic position in global markets.

  • 2-3. Role of Bio-Health in the National Economy

  • The bio-health industry has carved a significant niche within South Korea's national economy, serving as both a driver of economic growth and a generator of employment. In 2023, the sector's contribution to the economy was underscored by its diverse range of products, which includes pharmaceuticals, cosmetics, and medical devices. As more than 28.6% of bio-health companies reported expansion into international markets, the industry's global engagement is pivotal for sustaining economic momentum. The integration of innovative technologies and focus on R&D initiatives reflect a strategic alignment with national economic policies aimed at enhancing competitiveness on the global stage. The perceived value of the sector not only supports employment but also stimulates advancements in healthcare technology, making it a key player in the larger context of South Korea's development.

3. Bio-Health Industry Growth Outlook

  • 3-1. 2030 Global Ranking Projection

  • As of April 25, 2025, projections indicate that South Korea's biohealth industry is set to reach a value of $370.3 billion by 2030, positioning it as the eighth largest biohealth market globally. This upward trajectory reflects a significant improvement from its 2023 valuation of $215.9 billion, which accounted for only 1.6% of the global market, ranking the nation 11th. According to the Korea Health Industry Development Institute (KHIDI), if current trends continue, South Korea will surpass several major economies, trailing only the United States, China, Japan, Germany, France, Brazil, and the United Kingdom.

  • 3-2. Projected Annual Growth Rate

  • The biohealth sector in South Korea is projected to grow at an annual rate nearing 9% from 2024 to 2030. This projection is a notable acceleration compared to the 5.7% average annual growth rate recorded from 2019 to 2023. This burgeoning growth is attributed to the integration of groundbreaking technologies, including artificial intelligence, big data, and digital therapeutics. These advancements are anticipated to enhance operational efficiencies and patient outcomes, solidifying South Korea's position as a leader in biohealth innovation by the end of the decade.

  • 3-3. Key Strategic Growth Drivers

  • Several strategic drivers will underpin the anticipated growth of South Korea’s biohealth industry. Firstly, the rapid adoption of AI diagnostics and bio-convergence is critical, optimizing healthcare delivery, improving accuracy in treatments, and enhancing patient management. Secondly, the e-commerce segment within healthcare is expanding, driven by a changing consumer landscape and increased accessibility to health products and services online. Moreover, robust clinical trial infrastructures will facilitate innovation, allowing for expedited development and validation of new therapies and medical devices. These drivers collectively position South Korea to not only achieve its 2030 goals but also to continue its rise within the global biohealth sector.

4. AI and Bio Convergence in Healthcare

  • 4-1. Market Size and Outlook of AI Diagnostics

  • As of 2025, the market for AI diagnostics within healthcare is experiencing significant growth, attributed to increasing demand for innovative solutions that enhance patient care and operational efficiency. According to the report published on April 14, 2025, the global AI healthcare market was projected to reach USD 490.96 billion by 2032, with an impressive compound annual growth rate (CAGR) of 41.8% from 2023 to 2030. In South Korea specifically, the AI diagnostics segment is anticipated to surge at a CAGR of 50.8%, escalating from USD 0.37 billion in 2023 to USD 6.67 billion by 2030. This rapid growth underscores South Korea's competitive positioning in the technological landscape, supported by homegrown companies like Lunit and Vuno that are leading in medical image analysis.

  • By application area, significant investments in patient data analysis, medical imaging, and lifestyle management highlight the strategic priorities within the AI diagnostics market. Medical imaging, for instance, is cited as a crucial segment expected to thrive, leveraging advancements in algorithm-based analysis to deliver quicker and more accurate diagnoses. The domestic enhancement of AI technologies not only serves local health needs but is also aimed at establishing a strong foothold in international markets.

  • 4-2. Domestic vs. Global AI Trends

  • In comparison to global trends, South Korea is poised to emerge as a notable player in the AI healthcare landscape, particularly in the domain of diagnostics and digital health solutions. While North America maintains the largest share of the market at USD 72 billion, rapid growth is anticipated in the Asian region, with projections indicating that Asia's AI healthcare market may reach USD 49.4 billion by 2030. South Korea's projected growth rate not only outpaces the global average but also reflects robust local innovation and investment in AI capabilities.

  • The local healthcare sector is actively integrating AI technologies across various spectrums, from diagnostic tools to operational management. Examples include partnerships with global firms in the AI medical space, facilitating knowledge and technology exchange. South Korean firms are also engaging in international projects, such as the Cancer Moonshot Project, which signifies their growing recognition and competitive edge in global markets.

  • 4-3. Implementation Challenges

  • Despite the promising market outlook and strong growth potential, the implementation of AI in healthcare within South Korea faces several notable challenges. Primary among these are regulatory hurdles, which can impede the speed at which new technologies receive approval for clinical use. The infrastructure for data sharing and integration across healthcare systems also remains inconsistent, affecting the ability to leverage AI capabilities effectively.

  • Furthermore, there is a pressing need for a workforce that is not only trained in technological operations but also proficient in understanding clinical applications. This skills gap represents a critical concern as the industry grapples with the integration of AI systems into existing workflows. Addressing these challenges will be essential for South Korea to realize the full potential of AI in healthcare and maintain its competitive advantage globally.

5. Digital Transformation and E-Commerce

  • 5-1. Drivers of Healthcare E-Commerce Expansion

  • The healthcare e-commerce market is experiencing significant growth, with the global market valued at approximately USD 887.34 billion in 2023 and projected to reach USD 1, 362.15 billion by 2033, demonstrating a compound annual growth rate (CAGR) of 16.27% from 2024 to 2033. This expansion is enabled by several key drivers. First, changing consumer behaviors are at the forefront, as patients are increasingly seeking convenience in their healthcare purchases. The preferences for home delivery and contactless transactions reflect a broader shift towards digital solutions, especially highlighted during the COVID-19 pandemic. As a result, healthcare organizations—from independent pharmacies to large health systems—are adopting e-commerce platforms to diversify revenue streams and enhance patient engagement. Second, advancements in digital infrastructure play a crucial role. The integration of telehealth services and electronic health records (EHR) is allowing for seamless workflows that prioritize patient ease and interaction. Telehealth services connect patients with healthcare providers for consultations and prescription renewals, expanding the reach of traditional healthcare delivery models. Lastly, regulatory efforts aimed at streamlining telehealth prescriptions during the pandemic have led to sustained changes in legislation, further supporting healthcare e-commerce growth. As regions clarify their regulations concerning online sales of medical products, the potential for market participation increases, laying the groundwork for future innovations.

  • 5-2. Digital-First Strategies among Providers

  • Healthcare providers are increasingly implementing digital-first strategies that prioritize technology and e-commerce solutions to enrich patient interactions and streamline operations. These strategies encompass a range of services, such as online pharmacy and teleconsultation, which allow for efficient medication management and healthcare access. Online pharmacies facilitate the electronic submission of prescriptions and direct-to-consumer sales of medications, including prescription drugs and over-the-counter products. This not only enhances patient convenience but also decreases the operational burden on traditional pharmacies. Providers are able to manage inventories better and ensure timely delivery of medications through partnerships with third-party logistics companies. Telehealth services have surged alongside these digital adaptations, offering patients remote access to healthcare professionals via secure video consultations. These services offer both diagnosis and treatment options, reducing barriers to care, particularly for individuals with mobility or transportation challenges. The shift to digital healthcare platforms also allows providers to gather valuable data on patient interactions, thus enabling personalized care approaches that can improve patient outcomes and satisfaction. Overall, the combination of e-commerce and digital healthcare innovations is paving the way for a more patient-centric system that not only meets user needs more effectively but also prepares the sector for further advancements as technology evolves.

6. Clinical Trials Leadership

  • 6-1. Rise of South Korea as a Clinical-Trial Hub

  • South Korea has increasingly emerged as a key destination for global clinical trials, with the number of studies conducted in the country skyrocketing from just 48 in the year 2000 to over 1, 000 annually by 2021. This substantial growth reflects the changing landscape of clinical research, where emerging markets, particularly in the Asia-Pacific region, are gaining prominence. By 2021, approximately half of all clinical trials initiated globally featured a site in Asia-Pacific, highlighting the region's expanding role in drug development. The effective strategy implemented since the early 2000s has successfully positioned South Korea as a significant player within this sphere, driven by government initiatives and extensive support for developing robust clinical research capabilities.

  • Factors contributing to this shift include South Korea's high patient population density, which allows for quicker patient recruitment, and the availability of a well-established healthcare infrastructure that fosters efficient trial management. According to the latest statistics, South Korea ranked 4th globally for sponsor-initiated clinical trials in 2023, further solidifying its reputation as a reliable environment for clinical research.

  • 6-2. Regulatory and Infrastructure Support

  • The regulatory framework in South Korea has evolved significantly to speed up the clinical trial process. The Clinical Trial Authorization (CTA) allows simultaneous submission to both the Ministry of Food and Drug Safety (MFDS) and Independent Review Boards (IRBs), dramatically reducing waiting times. On average, the IRB review takes around three weeks, and the MFDS provides feedback within 30 working days. This efficient regulatory environment is instrumental in positioning South Korea as a competitive option for conducting clinical trials compared to other countries, with a total timeline from CTA submission to site initiation visit averaging just 112 days, making it the 6th fastest among 16 major countries.

  • Additionally, South Korea's government provides substantial support for research and development initiatives, reinforcing trust in the oversight of clinical trials. The lack of Official Actions Indicated from the US FDA during inspections from 2008 to 2019 illustrates the strict adherence to regulatory compliance by clinical trial sites. More than 200 institutions across the country are certified to conduct clinical trials, with major medical centers like Samsung Medical Center and Asan Medical Center leading the charge.

  • 6-3. Emerging Research Trends

  • Current trends in clinical research in South Korea indicate a growing focus on early-phase and oncology trials, areas where South Korea enjoys a strategic advantage. The global pharmaceutical industry recognizes this trend, as evidenced by an increase in investments in South Korean trials due to the reduced timeline for trial initiation and superior patient recruitment capabilities. The integration of advanced technologies, such as artificial intelligence and real-time data analytics, is also becoming more prevalent, enhancing trial design and execution.

  • In recent years, initiatives have been put in place that not only expedite clinical trial operations but also improve data quality and safety standards. South Korea's participation in international harmonization efforts, such as becoming a member of the International Council for Harmonization (ICH), underscores its commitment to aligning with global best practices, which is increasingly crucial in the interconnected world of clinical research.

7. International Collaborations and Medical Device Sector

  • 7-1. EU Business Hub’s Healthcare Mission

  • The EU Business Hub's Healthcare and Medical Equipment Korea 2025 mission marks a significant international collaboration initiative aimed at fostering ties between European small and medium-sized enterprises (SMEs) and South Korean businesses. Set to facilitate meaningful exchanges, the mission includes a five-day agenda comprising networking events, matchmaking sessions, and a visit to the Korea International Medical & Hospital Equipment Show (KIMES) 2025. This event not only aims to bolster EU SMEs' international presence but also helps them capitalize on South Korea's status as the 11th largest market in medical devices globally, with a keen focus on sectors like telemedicine, AI applications, and regenerative medicine.

  • 7-2. Participation of Foreign SMEs

  • As of May 7, 2025, 50 European SMEs, including start-ups, have actively engaged in the Healthcare and Medical Equipment Korea 2025 mission. This initiative is geared toward enhancing foreign participation in South Korea's medical device landscape, aiming to build robust and long-term partnerships with local industry players. By offering market insights, financial support, and cultural and linguistic assistance, the mission not only seeks to facilitate entry into the South Korean market but also promotes knowledge exchange and the adaptation of innovative healthcare solutions tailored to the unique demands of the region.

  • 7-3. Opportunities in the Medical Device Market

  • The South Korean medical device market presents considerable opportunities for international stakeholders, driven by a combination of demographic shifts and increasing healthcare expenditures. With the country transitioning into a super-aged society by 2025, where over 20.6% of its population will be over 65, there is an escalating demand for advanced healthcare technologies and services. Additionally, South Korean policies aimed at integrating data-driven and AI-based healthcare solutions are paving the way for innovative medical devices, thereby positioning Korea as a critical player in the global medical device industry.

8. Medical Education and Social Demand

  • 8-1. Analysis of Public Demand for Doctors (2016–2020)

  • Between 2016 and 2020, a significant analysis of public demand for doctors and healthcare services in South Korea was conducted through a comprehensive review of newspaper articles. This analysis, encapsulated in the study 'Analysis of Social Needs for Doctors and Medicine through a Keyword Analysis of Newspaper Articles, ' demonstrates evolving public perceptions and expectations towards medical professionals over the years. Specifically, the study reviewed 2, 068 articles across major journalistic outlets, identifying notable increases in discussions surrounding the roles and competencies of doctors.

  • Key findings from the keyword analysis indicate an escalating societal emphasis on doctors needing multidisciplinary competencies that extend beyond traditional medical knowledge. This shift reflects a broader societal demand for 'patient-centered care' and responsiveness to healthcare challenges, particularly in light of significant events such as the COVID-19 pandemic. Topics that emerged prominently during the analysis included healthcare technology, public safety in medicine, and the conflict between medical professionals and governmental policies regarding healthcare access and quality.

  • Moreover, the dataset highlighted an increasing prevalence of topics related to digital healthcare solutions and communicable disease management, indicating a societal expectation for doctors to be adept in utilizing modern healthcare innovations. For instance, in 2020, keywords reflecting the tension around the healthcare resource distribution during the COVID-19 pandemic became prevalent, further illustrating the pressing need for doctors who can navigate crisis conditions with competence and care.

  • 8-2. Implications for Training and Curriculum

  • The insights gained from the analysis of public demand have profound implications for medical education and training curriculums in South Korea. In response to the indicated expectations, medical schools and training institutions are increasingly encouraged to adopt a more comprehensive, interdisciplinary approach in structuring their programs. This means integrating not just clinical skills and medical knowledge, but also communication, ethics, and technology utilization into the doctor training framework.

  • Additionally, the findings advocate for the incorporation of public health education within medical curriculums, emphasizing the importance of understanding systemic healthcare issues, which have been highlighted through previous societal demands. The recent emphasis on patient-centered frameworks signals a pivotal shift towards training future healthcare professionals to operate effectively within a collaborative, communicative, and responsive healthcare environment.

  • Further, the data shows that the dynamics of the healthcare workforce in South Korea require ongoing adjustments in educational strategies. As public expectations evolve, so must medical training institutions actively revise their curriculums to equip students with essential skills that reflect the complexity of modern healthcare delivery. The resilience of the healthcare system depends significantly on how well medical education can adapt to these social demands and integrate flexible learning paths for aspiring healthcare professionals.

9. Medical Dispute Resolution for Foreign Patients

  • 9-1. Strategies for Handling Disputes

  • As of May 2025, the increasing influx of foreign patients into South Korea's healthcare system has underscored the need for effective dispute resolution strategies. Although disputes involving foreign patients are not yet officially recognized as a widespread problem, there remains significant complexity due to differences in language, nationality, and cultural expectations. To address potential grievances preemptively, healthcare institutions in Korea are advised to adopt comprehensive communication protocols and establish multilingual support teams. These teams would not only assist in overcoming language barriers but also provide proactive outreach to foreign patients to ensure their needs and expectations are being met. Ensuring clarity in the informed consent process is vital, particularly in procedures that may diverge from what patients might expect from their healthcare providers in their home countries. Furthermore, educational campaigns aimed at foreign patients regarding their rights within the Korean healthcare system could serve to mitigate misunderstandings before they escalate into disputes.

  • 9-2. Arbitration Framework and Agency Roles

  • The arbitration framework for resolving disputes involving foreign patients in South Korea is evolving, particularly in light of the growing prominence of medical tourism. Recent initiatives suggest the establishment of dedicated agencies that can oversee dispute resolution specifically for foreign patients. These agencies would collaborate with local healthcare providers to streamline processes for complaints regarding medical services. Moreover, the paper "A Study on the Strategy for Medical Disputes of Foreign Patients" highlights the necessity of intertwining these agencies with existing health systems to facilitate a smoother arbitration process. Utilizing established arbitration laws and integrating cultural mediation strategies can further enhance the effectiveness of dispute resolution. Effective training for medical personnel on cultural sensitivity and legal standards relating to foreign patients will be imperative in these frameworks.

  • 9-3. Implications for Medical Tourism

  • The implications of improved medical dispute resolution mechanisms for medical tourism in South Korea are substantial. A responsive and well-structured dispute resolution system can serve as a competitive advantage, positioning South Korea favorably against other prominent medical tourism destinations such as Thailand or Singapore. The convenience and transparency of a clear dispute resolution protocol can enhance the trust foreign patients place in Korean medical services, potentially increasing repeat visits and encouraging positive word-of-mouth recommendations. Furthermore, the government's endorsement and facilitation of these resolution strategies could attract even more foreign patients, bolstering South Korea's position in the global healthcare market. By prioritizing patient satisfaction and safety through proactive dispute handling, Korea can cement its reputation as a premier destination for medical care.

Conclusion

  • In conclusion, South Korea's healthcare industry in 2025 presents a compelling blend of robust domestic achievements alongside ambitious aspirations for global prominence. Although overall bio-health sales faced a modest decline in 2023, the persistent strength exhibited in pharmaceuticals and R&D—coupled with the projection of ascending to the 8th place globally by 2030—reflects significant resilience in the face of adversity. Innovation is primarily driven by advancements in AI diagnostics and bio-convergence, while the simultaneous growth of e-commerce platforms and enhanced clinical trial capabilities effectively fuels market expansion.

  • The commitment to international collaborations, as demonstrated by initiatives such as the EU mission and the establishment of effective dispute-resolution strategies for foreign patients, underscores Korea's competitive stance on the global health stage. To maintain and amplify this momentum, stakeholders must prioritize the upskilling of healthcare professionals, cultivate public-private partnerships, and streamline regulatory frameworks to facilitate the swift approval of medical devices and clinical trials. As the landscape shifts, future research will be critical to monitoring post-2025 performance metrics and assessing the tangible impacts of AI-enabled healthcare solutions. Looking forward, South Korea positions itself not just as a regional leader but as a potential global hub for innovation in healthcare.

Glossary

  • Bio-Health Industry: The bio-health industry encompasses a range of sectors related to health, including pharmaceuticals, biotechnology, and medical devices. This sector in South Korea is projected to grow significantly, driven by biotechnology innovations, particularly in AI diagnostics and e-commerce solutions related to health products, aiming for a global ranking of 8th by 2030.
  • Pharmaceutical: The pharmaceutical sector is a critical component of the bio-health industry, focusing on the development, production, and marketing of medications. In 2023, it reported significant growth, with revenues of ₩53.8 trillion, showcasing resilience amid an overall market contraction.
  • R&D (Research and Development): R&D refers to the systematic activities that lead to innovation and improvements in products or services. In South Korea's healthcare industry, R&D investment rose by 18.5% to ₩7.4 trillion in 2023, indicating a strong commitment to advancing medical technologies and solutions.
  • AI Diagnostics: AI diagnostics involve the use of artificial intelligence technologies to analyze medical data and enhance diagnostic accuracy. By May 2025, this market is projected to grow significantly in South Korea, with an expected compound annual growth rate of 50.8% through 2030, positioning the country as a leader in AI applications in healthcare.
  • Bio Convergence: Bio convergence is the integration of biotechnology with other scientific disciplines to create innovative health solutions. This emerging trend is key to improving healthcare delivery in South Korea, optimizing treatment accuracy and enhancing patient management across the bio-health sector.
  • E-Commerce in Healthcare: E-commerce in healthcare refers to the online buying and selling of medical products and services. As of May 2025, this segment is rapidly growing, driven by consumer demand for convenience and innovative digital platforms, contributing to an increased market engagement in the healthcare sector.
  • Clinical Trials: Clinical trials are research studies conducted with human participants to evaluate medical, surgical, or behavioral interventions. South Korea has rapidly emerged as a hub for clinical trials, with significant growth in the number of studies conducted, aided by government support and an efficient regulatory environment.
  • Medical Device: Medical devices are instruments, machines, or implants used to diagnose, prevent, monitor, or treat health conditions. The South Korean market for medical devices is notably competitive, driven by demographic shifts and policy advancements aimed at integrating technology into healthcare.
  • Foreign Patients: Foreign patients refer to individuals seeking medical care outside their home countries. As of May 2025, South Korea experiences a growing influx of these patients, necessitating robust dispute resolution mechanisms to address language and cultural barriers within its healthcare system.
  • Dispute Resolution: Dispute resolution pertains to processes for resolving conflicts or disagreements arising in healthcare settings. The increasing number of foreign patients stresses the importance of developing effective communication and dispute handling strategies to ensure patient satisfaction and protect rights.
  • Digital Transformation: Digital transformation in healthcare involves employing digital technologies to enhance healthcare delivery and patient experiences. As of May 2025, this is an essential aspect of the healthcare sector’s evolution, underpinning the rise of telehealth and e-commerce solutions.
  • EU Business Hub: The EU Business Hub is a network initiative aimed at supporting European small and medium-sized enterprises (SMEs) in accessing international markets, including South Korea. The Healthcare and Medical Equipment Korea 2025 mission is an example of this initiative, promoting collaboration and partnerships within the healthcare sector.
  • Growth Outlook: Growth outlook refers to the projected expansion of an industry or market over a defined period. The South Korean bio-health industry is projected to grow nearly 9% annually between 2024 and 2030, reflecting strong technological integration and market engagement.
  • Medical Education: Medical education involves training healthcare professionals in clinical skills, medical knowledge, and patient care. Current demands for a more responsive curriculum in South Korea are driven by evolving public expectations and the complexities of modern healthcare challenges.

Source Documents